1007 GMT - AstraZeneca has a robust and diverse portfolio, with strong opportunities in its pipeline, analysts at Berenberg say in a note. The pharmaceutical company is on track to deliver 13% return on research and development investment for its current pipeline cohort, they say. There have been some failures of highly anticipated readouts in 2026, but these were offset by other positive results, highlighting the importance of having a diverse portfolio, they add. Shares are up 2.25% at $163.78.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.